Opus Genetics filed a revised OPGx-BEST1 presentation correcting an error in the conversion of logMAR visual acuity to ETDRS letters for the five-patient low-dose Cohort 1 of the open-label Phase I/II BIRD-1 study in…
Pyxis Oncology reported updated Phase I monotherapy data for micvotabart pelidotin, or MICVO, in second-line or later recurrent or metastatic head and neck squamous-cell carcinoma. Among 33 efficacy-evaluable patients treated at 5.4 mg/kg every…
TwoStep Therapeutics closed an oversubscribed $62.5 million Series A and received FDA clearance to begin first-in-human testing of TS-104, a peptide-drug conjugate designed to bind five tumor-associated integrins. The financing funds Phase I development,…
A Nature paper published online September 9 reports that TRI-611 is an oral, brain-penetrant cereblon molecular-glue degrader that binds a distal ALK surface and eliminates wild-type and kinase-inhibitor-resistant ALK fusion proteins. The compound drove…
Pyxis Oncology appointed Thomas Civik permanent Chief Executive Officer and Chairman of the Board effective September 4, 2026. Civik had served as interim CEO since February 2 and has been a director since 2021….
Bristol Myers Squibb said the registrational Phase II QUINTESSENTIAL study of arlocabtagene autoleucel met its primary overall-response-rate endpoint and key complete-response-rate endpoint in quadruple-class-exposed relapsed or refractory multiple myeloma after at least four prior…
Novartis disclosed that Phase III HARBOR did not show a statistically significant improvement versus placebo on video hand opening time, the primary endpoint in myotonic dystrophy type 1. The company reported evidence of activity…
Mirum Pharmaceuticals appointed Rob Myers, M.D., chief medical officer effective September 21, 2026. He succeeds Joanne Quan, M.D., who is departing; the company did not disclose her effective departure date, reason, next destination or…
FDA accepted Intellia Therapeutics’ biologics license application for lonvoguran ziclumeran, or lonvo-z, granted Priority Review and set a March 10, 2027 target action date. FDA advised the company that it is not currently planning…
Moonwalk Biosciences closed an oversubscribed $70 million Series B co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly, Gaorong Ventures and existing investors ARCH Venture Partners, Khosla Ventures and Future Ventures….
